GlassScriptPhysician profile
Amanda M Brandon
NPI 1023445277
$1,954.74
in general payments reported to CMS, 2019-2025
19 companies · $340 in 2025
The $340 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $191 · 2023: $796 · 2024: $627 · 2025: $340.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,763.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,763.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $488.98 | 2022-2025 | Verquvo, Dificid, Recarbrio |
| Astrazeneca Pharmaceuticals LP | $235.61 | 2022-2025 | Farxiga |
| Pfizer INC. | $213.44 | 2022-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $191.19 | 2022-2024 | Lifevest |
| Abbvie INC. | $152.87 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $129.57 | 2022-2025 | Jardiance |
| Novo Nordisk INC | $81.06 | 2024 | Ozempic |
| Novartis Pharmaceuticals Corporation | $73.29 | 2024 | |
| Lexicon Pharmaceuticals, INC. | $70.34 | 2023-2024 | Inpefa |
| Melinta Therapeutics, LLC | $65.43 | 2023 | Kimyrsa, Vabomere, Rezzayo |
| Bayer Healthcare Pharmaceuticals INC. | $53.68 | 2022-2025 | |
| Aimmune Therapeutics, INC. | $44.79 | 2023 | |
| Kestra Medical Technology Services, INC. | $42.01 | 2025 | Assure Wcd |
| Hologic Sales and Service, LLC | $23.10 | 2025 | Aptima, Thinprep 2000 Processor |
| Abbott Laboratories | $23.04 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $21.23 | 2024 | |
| Alnylam Pharmaceuticals INC. | $18.06 | 2025 | Onpattro |
| Paratek Pharmaceuticals, INC. | $13.57 | 2024 | Nuzyra |
| Ferring Pharmaceuticals INC. | $13.48 | 2023 | Rebyota |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Brandon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.